Emergent BioSolutions Inc (EBS)
8.77
-0.35
(-3.84%)
USD |
NYSE |
Nov 04, 16:00
9.01
+0.24
(+2.74%)
After-Hours: 20:00
Emergent BioSolutions Enterprise Value: 1.256B for Nov. 4, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 04, 2024 | 1.256B |
| November 01, 2024 | 1.275B |
| October 31, 2024 | 1.272B |
| October 30, 2024 | 1.300B |
| October 29, 2024 | 1.286B |
| October 28, 2024 | 1.304B |
| October 25, 2024 | 1.265B |
| October 24, 2024 | 1.272B |
| October 23, 2024 | 1.255B |
| October 22, 2024 | 1.281B |
| October 21, 2024 | 1.331B |
| October 18, 2024 | 1.287B |
| October 17, 2024 | 1.276B |
| October 16, 2024 | 1.277B |
| October 15, 2024 | 1.279B |
| October 14, 2024 | 1.269B |
| October 11, 2024 | 1.255B |
| October 10, 2024 | 1.240B |
| October 09, 2024 | 1.265B |
| October 08, 2024 | 1.280B |
| October 07, 2024 | 1.279B |
| October 04, 2024 | 1.287B |
| October 03, 2024 | 1.265B |
| October 02, 2024 | 1.279B |
| October 01, 2024 | 1.241B |
| Date | Value |
|---|---|
| September 30, 2024 | 1.234B |
| September 27, 2024 | 1.189B |
| September 26, 2024 | 1.178B |
| September 25, 2024 | 1.107B |
| September 24, 2024 | 1.116B |
| September 23, 2024 | 1.113B |
| September 20, 2024 | 1.139B |
| September 19, 2024 | 1.162B |
| September 18, 2024 | 1.158B |
| September 17, 2024 | 1.156B |
| September 16, 2024 | 1.176B |
| September 13, 2024 | 1.209B |
| September 12, 2024 | 1.196B |
| September 11, 2024 | 1.193B |
| September 10, 2024 | 1.204B |
| September 09, 2024 | 1.199B |
| September 06, 2024 | 1.190B |
| September 05, 2024 | 1.196B |
| September 04, 2024 | 1.183B |
| September 03, 2024 | 1.183B |
| August 30, 2024 | 1.232B |
| August 29, 2024 | 1.264B |
| August 28, 2024 | 1.264B |
| August 27, 2024 | 1.283B |
| August 26, 2024 | 1.286B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
826.80M
Minimum
Feb 07 2024
7.660B
Maximum
Aug 13 2020
2.716B
Average
2.148B
Median
Jul 08 2022
Enterprise Value Benchmarks
| Geovax Labs Inc | 8.055M |
| Tonix Pharmaceuticals Holding Corp | 7.452M |
| Abbott Laboratories | 211.48B |
| SIGA Technologies Inc | 392.64M |
| Chimerix Inc | -59.43M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -283.10M |
| Revenue (Quarterly) | 248.10M |
| Total Expenses (Quarterly) | 424.40M |
| EPS Diluted (Quarterly) | -5.38 |
| Gross Profit Margin (Quarterly) | -19.35% |
| Profit Margin (Quarterly) | -114.1% |
| Earnings Yield | -128.2% |
| Normalized Earnings Yield | -68.95 |